Document Detail


Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.
MedLine Citation:
PMID:  23018631     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance, abnormally elevated hepatic glucose production, and reduced glucose-stimulated insulin secretion. Treatment with antihyperglycemic agents is initially successful in type 2 diabetes, but it is often associated with a high secondary failure rate, and the addition of insulin is eventually necessary for many patients, in order to restore acceptable glycemic control and to reduce the risk of development and progression of disease complications. Notably, even patients who appear to have similar requirements of antidiabetic regimens show great variability in drug disposition, glycemic response, tolerability, and incidence of adverse effects during treatment. Pharmacogenomics is a promising area of investigation and involves the search for genetic polymorphisms that may explain the interindividual variability in antidiabetic therapy response. The initial positive results portend that genomic efforts will be able to shed important light on variability in pharmacologic traits. In this review, we summarize the current understanding of genetic polymorphisms that may affect the responses of subjects with T2DM to antidiabetic treatment. These genes belong to three major classes: genes involved in drug metabolism and transporters that influence pharmacokinetics (including the cytochrome P450 [CYP] superfamily, the organic anion transporting polypeptide [OATP] family, and the polyspecific organic cation transporter [OCT] family); genes encoding drug targets and receptors (including peroxisome proliferator-activated receptor gamma [PPARG], the adenosine triphosphate [ATP]-sensitive potassium channel [K(ATP)], and incretin receptors); and genes involved in the causal pathway of T2DM that are able to modify the effects of drugs (including adipokines, transcription factor 7-like 2 (T cell specific, HMG-box) [TCF7L2], insulin receptor substrate 1 [IRS1], nitric oxide synthase 1 (neuronal) adaptor protein [NOS1AP], and solute carrier family 30 (zinc transporter), member 8 [SLC30A8]). In addition to these three major classes, we also review the available evidence on novel genes (CDK5 regulatory subunit associated protein 1-like 1 [CDKAL1], insulin-like growth factor 2 mRNA binding protein 2 [IGF2BP2], potassium voltage-gated channel, KQT-like subfamily, member 1 [KCNQ1], paired box 4 [PAX4] and neuronal differentiation 1 [NEUROD1] transcription factors, ataxia telangiectasia mutated [ATM], and serine racemase [SRR]) that have recently been proposed as possible modulators of therapeutic response in subjects with T2DM.
Authors:
Gaia Chiara Mannino; Giorgio Sesti
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Molecular diagnosis & therapy     Volume:  16     ISSN:  1179-2000     ISO Abbreviation:  Mol Diagn Ther     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-19     Completed Date:  2013-03-28     Revised Date:  2013-05-16    
Medline Journal Info:
Nlm Unique ID:  101264260     Medline TA:  Mol Diagn Ther     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  285-302     Citation Subset:  IM    
Affiliation:
Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adipokines / genetics,  metabolism
Cyclin-Dependent Kinase 5 / genetics,  metabolism
Diabetes Mellitus, Type 2 / drug therapy*,  genetics*
Humans
Hypoglycemic Agents / therapeutic use
Incretins / genetics,  metabolism
Insulin / blood,  secretion
Insulin Receptor Substrate Proteins / genetics,  metabolism
Insulin Resistance
Insulin-Like Growth Factor II / genetics,  metabolism
Ion Channels / genetics,  metabolism
Mitochondrial Proteins / genetics,  metabolism
Nicotinamide Phosphoribosyltransferase / genetics,  metabolism
Nitric Oxide Synthase Type I / genetics,  metabolism
PPAR gamma / genetics,  metabolism
Pharmacogenetics*
Polymorphism, Genetic
Racemases and Epimerases / genetics,  metabolism
Transcription Factor 7-Like 2 Protein / genetics,  metabolism
Chemical
Reg. No./Substance:
0/Adipokines; 0/CDKAL1 protein, human; 0/Hypoglycemic Agents; 0/IGF2 protein, human; 0/IRS1 protein, human; 0/Incretins; 0/Insulin; 0/Insulin Receptor Substrate Proteins; 0/Ion Channels; 0/Mitochondrial Proteins; 0/PPAR gamma; 0/TCF7L2 protein, human; 0/Transcription Factor 7-Like 2 Protein; 0/mitochondrial uncoupling protein 2; 67763-97-7/Insulin-Like Growth Factor II; EC 1.14.13.39/NOS1 protein, human; EC 1.14.13.39/Nitric Oxide Synthase Type I; EC 2.4.2.12/Nicotinamide Phosphoribosyltransferase; EC 2.7.11.22/CDK5 protein, human; EC 2.7.11.22/Cyclin-Dependent Kinase 5; EC 5.1.-/Racemases and Epimerases; EC 5.1.1.16/serine racemase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fibroblast autophagy in fibrotic disorders.
Next Document:  Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coron...